Tissue Injury Regulates Serotonin 1D Receptor Expression: Implications for the Control of Migraine and Inflammatory Pain
Open Access
- 9 August 2006
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 26 (32) , 8332-8338
- https://doi.org/10.1523/jneurosci.1989-06.2006
Abstract
The anti-migraine action of “triptan” drugs involves the activation of serotonin subtype 1D (5-HT1D) receptors expressed on “pain-responsive” trigeminal primary afferents. In the central terminals of these nociceptors, the receptor is concentrated on peptidergic dense core vesicles (DCVs) and is notably absent from the plasma membrane. Based on this arrangement, we hypothesized that in the resting state the receptor is not available for binding by a triptan, but that noxious stimulation of these afferents could trigger vesicular release of DCVs, thus externalizing the receptor. Here we report that within 5 min of an acute mechanical stimulus to the hindpaw of the rat, there is a significant increase of 5-HT1D-immunoreactivity (IR) in the ipsilateral dorsal horn of the spinal cord. We suggest that these rapid immunohistochemical changes reflect redistribution of sequestered receptor to the plasma membrane, where it is more readily detected. We also observed divergent changes in 5-HT1D-IR in inflammatory and nerve-injury models of persistent pain, occurring at least in part through the regulation of 5-HT1D-receptor gene expression. Finally, we found that 5-HT1D-IR is unchanged in the spinal cord dorsal horn of mice with a deletion of the gene encoding the neuropeptide substance P. This result differs from that reported for the ∂-opioid receptor, which is also sorted to DCVs, but is greatly reduced in preprotachykinin mutant mice. We suggest that a “pain”-triggered regulation of 5-HT1D-receptor expression underlies the effectiveness of triptans for the treatment of migraine. Moreover, the widespread expression of 5-HT1Dreceptor in somatic nociceptive afferents suggests that triptans could, in certain circumstances, treat pain in nontrigeminal regions of the body.Keywords
This publication has 43 references indexed in Scilit:
- Primary afferent tachykinins are required to experience moderate to intense painNature, 1998
- Chronic Paroxysmal Hemicrania and Hemicrania Continua: Lack of Efficacy of SumatriptanHeadache: The Journal of Head and Face Pain, 1998
- Localization and regulation of the delta-opioid receptor in dorsal root ganglia and spinal cord of the rat and monkey: evidence for association with the membrane of large dense-core vesiclesNeuroscience, 1997
- Inflammation Increases the Distribution of Dorsal Horn Neurons That Internalize the Neurokinin-1 Receptor in Response to Noxious and Non-Noxious StimulationJournal of Neuroscience, 1997
- Atypical facial pain: A double-blind placebo-controlled crossover pilot study of subcutaneous sumatriptan.European Neuropsychopharmacology, 1997
- Sensitization of meningeal sensory neurons and the origin of headachesNature, 1996
- Is myofascial pain of the temporal muscles relieved by oral sumatriptan? A cross-over pilot studyPain, 1995
- Cluster Headache Attacks Treated for Up Three Months with Subcutaneous Sumatriptan (6 mg)Cephalalgia, 1995
- Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of ratsNeuropharmacology, 1995
- Activation of spinal delta-1 or delta-2 opioid receptors reduces carrageenan-induced hyperalgesia in the rat.1994